Therapeutic area COVID-19/Coronavirus
Background info
Intellectual property

What the technology does

The S protein variants of SARS-CoV-2 can be used as a reagent for diagnostic testing (ELISA or other antibody tests), and as a component of vaccines (for example as a sequence in a nucleic acid vaccine, as part of an attenuated viral vaccine, or as a protein based vaccine). It can also be used as a reagent to isolate antibody producing B cells. Some of the variants are described in the publication below and latest variants are still unpublished.


The S protein undergoes conformational changes to interact with its receptor and to mediate fusion with the target cell. It is also unstable, and prone to denaturation resulting in changes to its structure and antigenic characteristics. These sequence variants can lead to the generation of proteins with increased stability and conformation which may give better performance in diagnostics or vaccines.

Main application field

R&D, vaccine, therapeutic and diagnostic development


Non-exclusive licence


View Publication

Key Contact

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities